Thermo Fisher Scientific EDA2R Polyclonal Antibody

Applications

Tested Dilution

Publications

Immunocytochemistry (ICC/IF)

0.25-2 µg/mL

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Recombinant Human EDA2R. Recombinant protein control fragment (Product #RP-106549).

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.05 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS, pH 7.2, with 40% glycerol

Contains

0.02% sodium azide

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Wet ice

RRID

AB_2664820

Product Specific Information

Immunogen sequence: CQENEYWDQWG RCVTCQRCGP GQELSKDCGY GEGGDAYCTA CPPRRYKSSW GHHKCQSCIT CAVINRVQKV NCTATS

Highest antigen sequence identity to the following orthologs - mouse 86%, rat 88%.

Target Information

X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-kappa-B and JNK pathways. Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis. The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.